Eloxx Pharmaceuticals, Inc. (ELOX) stock
ELOXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 7/30
$10.41−1.33 (-11.33%)
Close on Nov 18, 2026Market cap $70.68MP/E –Yield –
Eloxx Pharmaceuticals total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
Eloxx Pharmaceuticals's total debt was $0 at Jun 30, 2026. For fiscal 2025 it was $1.00M, down 84.7% from the year before. The highest annual figure on record is $14.84M in fiscal 2019.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.00M | -84.7% |
| FY2024 | Dec 31, 2024 | $6.52M | +70.1% |
| FY2023 | Dec 31, 2023 | $3.83M | -69.4% |
| FY2022 | Dec 31, 2022 | $12.54M | +4.5% |
| FY2021 | Dec 31, 2021 | $12.00M | +3.3% |
| FY2020 | Dec 31, 2020 | $11.62M | -21.7% |
| FY2019 | Dec 31, 2019 | $14.84M | – |
Quarterly total debt
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026CQ2 2026 | Jun 30, 2026 | $0 | -100.0% |
| Q1 FY2026CQ1 2026 | Mar 31, 2026 | $0 | -100.0% |
| Q4 FY2025CQ4 2025 | Dec 31, 2025 | $1.00M | -82.2% |
| Q4 FY2024CQ4 2024 | Dec 31, 2024 | $6.52M | +17.1% |
| Q4 FY2023CQ4 2023 | Dec 31, 2023 | $3.83M | -69.4% |
| Q3 FY2023CQ3 2023 | Sep 30, 2023 | $5.44M | -56.1% |
| Q2 FY2023CQ2 2023 | Jun 30, 2023 | $5.61M | -54.2% |
| Q1 FY2023CQ1 2023 | Mar 31, 2023 | $5.56M | -54.1% |
| Q4 FY2022CQ4 2022 | Dec 31, 2022 | $12.54M | +4.5% |
| Q3 FY2022CQ3 2022 | Sep 30, 2022 | $12.39M | +4.0% |
| Q2 FY2022CQ2 2022 | Jun 30, 2022 | $12.25M | +31.4% |
| Q1 FY2022CQ1 2022 | Mar 31, 2022 | $12.12M | +15.7% |
| Q4 FY2021CQ4 2021 | Dec 31, 2021 | $12.00M | +3.3% |
| Q3 FY2021CQ3 2021 | Sep 30, 2021 | $11.91M | -6.5% |
| Q2 FY2021CQ2 2021 | Jun 30, 2021 | $9.32M | -32.7% |
| Q1 FY2021CQ1 2021 | Mar 31, 2021 | $10.48M | -26.0% |
| Q4 FY2020CQ4 2020 | Dec 31, 2020 | $11.62M | -21.7% |
| Q3 FY2020CQ3 2020 | Sep 30, 2020 | $12.74M | -13.2% |
| Q2 FY2020CQ2 2020 | Jun 30, 2020 | $13.85M | -4.7% |
| Q1 FY2020CQ1 2020 | Mar 31, 2020 | $14.16M | -1.6% |
| Q4 FY2019CQ4 2019 | Dec 31, 2019 | $14.84M | – |
| Q3 FY2019CQ3 2019 | Sep 30, 2019 | $14.68M | – |
| Q2 FY2019CQ2 2019 | Jun 30, 2019 | $14.54M | – |
| Q1 FY2019CQ1 2019 | Mar 31, 2019 | $14.39M | – |
See a number that looks wrong?